Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Trial details
- Registry ID
- NCT04452591
- Drugs studied
- Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside
TrialRedline tracks 4 clinical trials sponsored by CG Oncology, Inc.: 2 Phase 3, 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-GuerinNCT04452591 | Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside | Active not recruiting | 2030-06-16Estimated |
| A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTNCT06111235 | Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside | Active not recruiting | 2026-11Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBCNCT06567743 | Cretostimogene Grenadenorepvec | Recruiting | 2027-03-31Estimated |
| Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-GuerinNCT04387461 | CG0070, Pembrolizumab Injection, n-dodecyl-B-D-maltoside | Completed | 2023-03-07Actual |
Names as written in the registry records.
NCT06111235 · CG Oncology, Inc.
Before: Jun 2026. After: Nov 2026.
NCT04452591 · CG Oncology, Inc.
Before: 24 Dec 2027. After: 16 Jun 2030.
NCT06111235 · CG Oncology, Inc.
Before: Jan 2028. After: Jun 2026.